A/Prof Dusan Kotasek

Medical Oncologist
Become a Patient

A/Prof Dusan Kotasek is a strong advocate for clinical trials, committed to ensuring South Australian patients have access to the latest in clinical research closer to home.


A/Prof Dusan Kotasek is Clinical Research Director of Ashford Cancer Centre Research (ACCR) at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. In 1980 he graduated from the University of Adelaide with a Bachelor of Medicine, Bachelor of Surgery (Hons) and then commenced specialist training at The Queen Elizabeth Hospital. A/Prof Kotasek subsequently completed a three-year fellowship at the University of Minneapolis before returning to Adelaide as a consultant medical oncologist at The Queen Elizabeth Hospital in 1988.

In 1995 he co-founded Adelaide Cancer Centre, now known as Icon Cancer Centre Adelaide, with Dr Francis Parnis. Over the past 25 years, the centre has grown into the largest private oncology facility in South Australia. A/Prof Kotasek has published over 160 articles and abstracts in peer-reviewed journals and has served on several oncology advisory boards including the Medical Oncology Group of Australia (MOGA).

In September 2019 A/Prof Kotasek retired from clinical practice and was appointed as Clinical Research Director of Ashford Cancer Centre Research. ACCR offer South Australia’s leading private cancer clinical trials program, focusing on phase I and first-in-human studies of cancer drugs at both Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens.

Affiliations & Memberships

  • Royal Australasian College of Physicians (RACP)

Special Interests

  • Clinical research

Icon Locations

Adelaide (Kurralta Park) View centre
Adelaide (Windsor Gardens) View centre


  • Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. A. Gronchi, S. Bonvalot, A. Velasco, D. Kotasek, P. Rutkowski, P. Hohenberger, E. Fumagalli, I. Judson, A. Italiano, H. Gelderblom, F. Coevorden, N. Penel, H. Kopp, F. Duffaud, D. Goldstein, J. Broto, E. Wardelmann, S. Marréaud, B. Smithers & P. Casali. JAMA Surgery, 2020; 155(6): e200397.

  • Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma. D. Kotasek, A. Nagrial, S. Lumba, N. Tebbutt, T. George, S. Smith, S. Gagnon, M. Cullen & M. Walker. Journal of Clinical Oncology, 2020; 38(4_suppl): 710.

  • Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study. R. Perets, K. Yoh, D. Kim, J. Bar, M. Ahn, A. Nagrial, M. Satouchi, D. Rasco, D. Lee, D. Spigel, D. Kotasek, M. Gutierrez, J. Niu, S. Siddiqi, A. Chain, B. Butts, X. Li, J. Cyrus, R. Altura & B. Cho. Journal of Clinical Oncology, 2020; 37(15_suppl): 2558.

  • First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors. C. Bier, M. Millward, D. Kotasek, K. Gorelick & J. Goldberg. Journal of Clinical Oncology, 2019; 3(15_suppl): 2600.

  • Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. M. Mckeage, D. Kotasek, B. Markman, M. Hidalgo, M. Millward, M. Jameson, D. Harris, R. Stagg, A. Kapoun, L. Xu & B. Hughes. Targeted Oncology, 2017;. 13(12).